LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Britain Courts Anthropic Amid US Defense Department Dispute 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
REDWOOD CITY, Calif., Aug. 31, 2016 -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) a clinical development-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced that Paul J. Hastings, Chairman and Chief Executive Officer, will provide a corporate update at two upcoming investor conferences.
- 2016 Wells Fargo Healthcare Conference
OncoMed’s corporate presentation is scheduled for 2:55 pm ET on September 8, 2016 in Boston, MA.
- Leerink Partners Roundtable Series: Rare Diseases and Immuno-Oncology
Paul Hastings will provide a fireside chat on Thursday, September 29 at 1:30 pm ET in New York City.
A live webcast of each presentation will be available through the OncoMed website in the Investor Relations section. The webcast will also be archived and available for replay for up to 45 days.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics. OncoMed has seven anti-cancer therapeutic candidates in clinical development, including demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), brontictuzumab (anti-Notch1, OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), ipafricept (FZD8-Fc, OMP-54F28), and anti-RSPO3 (OMP-131R10), which each target key cancer stem cell signaling pathways including Notch, Wnt and R-spondin LGR. OncoMed is advancing its wholly owned GITRL-Fc candidate and an undisclosed immuno-oncology candidate (IO#2) toward clinical trials in the 2016-2017 timeframe. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK).
Additional information can be found at the company's website: www.oncomed.com.
Contact:
Media & Investors
OncoMed Pharmaceuticals
Michelle Corral
Senior Director, Investor Relations and Corporate Communications
[email protected]
(650) 995-8373
